amifostine anhydrous has been researched along with Melanoma in 12 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In Europe fotemustine (Muphoran) is widely used in the treatment of brain metastases in melanoma patients." | 9.08 | Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study. ( Breitbart, E; Makki, A; Mohr, P; Schadendorf, D, 1998) |
| "Fotemustine (Muphoran, S10036), a nitrosourea derivative active in the treatment of malignant melanoma and primary brain tumors, was evaluated in combination with the free radicals cytoprotective agent amifostine (Ethyol, WR-2721) and its alkaline phosphatase (AP)-generated active metabolite WR-1065 in four human melanoma (RPMI-7950, SK-MEL2, SK-MEL5 and WM-115) and lung fibroblast (MRC-5) cell lines." | 7.71 | Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines. ( Berlion, M; Marchal, S; Merlin, JL; Poullain, MG; Ramacci, C, 2002) |
| "The effect of treatments with the hypoxic cell radiosensitizers misonidazole (MISO), SR-2508, RSU-1069, and with the radioprotector WR-2721 on spontaneously disseminated Lewis lung carcinoma (LLC) and B16 melanoma (B16M) was investigated." | 7.67 | Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice. ( Chapman, JD; Kanclerz, A, 1988) |
| " In Europe fotemustine (Muphoran) is widely used in the treatment of brain metastases in melanoma patients." | 5.08 | Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study. ( Breitbart, E; Makki, A; Mohr, P; Schadendorf, D, 1998) |
| "Fotemustine (Muphoran, S10036), a nitrosourea derivative active in the treatment of malignant melanoma and primary brain tumors, was evaluated in combination with the free radicals cytoprotective agent amifostine (Ethyol, WR-2721) and its alkaline phosphatase (AP)-generated active metabolite WR-1065 in four human melanoma (RPMI-7950, SK-MEL2, SK-MEL5 and WM-115) and lung fibroblast (MRC-5) cell lines." | 3.71 | Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines. ( Berlion, M; Marchal, S; Merlin, JL; Poullain, MG; Ramacci, C, 2002) |
| "The effect of treatments with the hypoxic cell radiosensitizers misonidazole (MISO), SR-2508, RSU-1069, and with the radioprotector WR-2721 on spontaneously disseminated Lewis lung carcinoma (LLC) and B16 melanoma (B16M) was investigated." | 3.67 | Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice. ( Chapman, JD; Kanclerz, A, 1988) |
| " The lack of improved duration of response or impact on survival may be the result of the limited improvement of efficacy with the higher dosage of cisplatin in conjunction with WR-2721, or the limited number of patients accrued to this study." | 2.71 | Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). ( Borden, E; Ewell, M; Glick, J; Glover, D; Ibrahim, J; Karp, D; Kirkwood, J; Stewart, J, 2003) |
| "The mechanism of action, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of amifostine are reviewed." | 2.40 | Amifostine for protection from antineoplastic drug toxicity. ( Foster-Nora, JA; Siden, R, 1997) |
| "Ototoxicity is a common side effect of high-dose cisplatin treatment." | 1.32 | High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. ( Ehrsson, H; Ekborn, A; Eksborg, S; Hansson, J; Laurell, G; Wagenius, G; Wallin, I, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glover, D | 2 |
| Ibrahim, J | 1 |
| Kirkwood, J | 1 |
| Glick, J | 1 |
| Karp, D | 1 |
| Stewart, J | 1 |
| Ewell, M | 1 |
| Borden, E | 1 |
| Ekborn, A | 1 |
| Hansson, J | 1 |
| Ehrsson, H | 1 |
| Eksborg, S | 1 |
| Wallin, I | 1 |
| Wagenius, G | 1 |
| Laurell, G | 1 |
| Millar, JL | 1 |
| McElwain, TJ | 1 |
| Clutterbuck, RD | 1 |
| Wist, EA | 1 |
| Bukowski, RM | 1 |
| Murthy, SA | 1 |
| Finke, J | 1 |
| Caulfield, MJ | 1 |
| Tubbs, R | 1 |
| Herzog, P | 1 |
| Stanley, J | 1 |
| Edinger, M | 1 |
| Tuason, L | 1 |
| McLain, D | 1 |
| Foster-Nora, JA | 1 |
| Siden, R | 1 |
| Mohr, P | 1 |
| Makki, A | 1 |
| Breitbart, E | 1 |
| Schadendorf, D | 1 |
| Merlin, JL | 1 |
| Marchal, S | 1 |
| Ramacci, C | 1 |
| Berlion, M | 1 |
| Poullain, MG | 1 |
| Demchak, PA | 1 |
| Mier, JW | 1 |
| Robert, NJ | 1 |
| O'Brien, K | 1 |
| Gould, JA | 1 |
| Atkins, MB | 1 |
| Glover, DJ | 1 |
| Buzaid, AC | 1 |
| Murren, J | 1 |
| Durivage, HJ | 1 |
| Kanclerz, A | 1 |
| Chapman, JD | 1 |
| Glick, JH | 1 |
| Weiler, C | 1 |
| Fox, K | 1 |
| Guerry, D | 1 |
1 review available for amifostine anhydrous and Melanoma
| Article | Year |
|---|---|
Amifostine for protection from antineoplastic drug toxicity.
Topics: Amifostine; Antineoplastic Agents; Clinical Trials as Topic; Hearing; Humans; Kidney; Melanoma; Neop | 1997 |
4 trials available for amifostine anhydrous and Melanoma
| Article | Year |
|---|---|
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Body Weight | 2003 |
Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.
Topics: Adult; Aged; Amifostine; Animals; Antibodies, Heterophile; Antibodies, Monoclonal; Cisplatin; Combin | 1994 |
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brai | 1998 |
High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug | 1991 |
7 other studies available for amifostine anhydrous and Melanoma
| Article | Year |
|---|---|
High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Audiometry, Pure-Tone; Auditory Threshold; Cisplatin | 2004 |
The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721).
Topics: Amifostine; Animals; Colony-Forming Units Assay; Female; Hematopoietic Stem Cells; Male; Melanoma; M | 1982 |
Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Drug Synergism; Humans; Inhibitory Concentration 5 | 2002 |
Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Female | 1991 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 1991 |
Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice.
Topics: Amifostine; Animals; Etanidazole; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred C57BL; Misonida | 1988 |
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; | 1987 |